Summary & Overview
HCPCS Level II J1837: Posaconazole Injection, 1 mg
HCPCS Level II code J1837 denotes a 1 mg unit of posaconazole administered as an injectable antifungal. Posaconazole is used for prevention and treatment of invasive fungal infections in high-risk patients, and billing at the milligram level makes accurate dosing and unit reporting critical for both clinical documentation and payer adjudication. Nationally, this code matters because injectable antifungal therapies can be high-cost and are commonly used in inpatient, outpatient infusion, and specialty care settings.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what the code represents, typical sites of service, and the clinical context for posaconazole injections. The publication also outlines benchmarking considerations, common billing practices, and policy-relevant points affecting coverage and reimbursement for antifungal infusions. This summary equips billing managers, clinicians, and policy analysts with the essential context needed to interpret claims carrying HCPCS Level II code J1837 and to understand its implications within national payer ecosystems.
Billing Code Overview
HCPCS Level II code J1837 represents an injection of posaconazole, with the unit described as 1 mg. This code is used to report administration of the antifungal agent posaconazole when billed per milligram.
-
Service type: Medication administration (intravenous or injectable antifungal therapy)
-
Typical site of service: Hospital inpatient, hospital outpatient department, ambulatory infusion center, or other clinical settings where injectable antifungal therapy is provided.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with invasive fungal infection risk (for example, immunocompromised patients receiving chemotherapy, hematopoietic stem cell transplant recipients, or patients with prolonged neutropenia) who requires antifungal therapy with posaconazole. The clinical workflow begins with infectious diseases consultation or oncology team assessment documenting the indication (such as prophylaxis against invasive Aspergillus and Candida or treatment of documented or suspected invasive mold infection). The medication order for J1837 (posaconazole, 1 mg) is entered in the electronic health record specifying total dose and route (intravenous or oral suspension/delayed‑release tablets as clinically appropriate). Pharmacy prepares the appropriate total milligram dose using the J1837 unit billing increments; nursing verifies patient identity, allergy status, IV access, and baseline labs (liver function tests), then administers the infusion or coordinates oral dosing. Documentation includes indication, dose, number of units billed, route, site of service (commonly inpatient hospital, outpatient infusion center, or ambulatory clinic), and any adverse reactions. Billing uses J1837 per milligram, with the total billed units matching the administered milligrams, and supporting clinical notes and medication administration records retained for audit and medical necessity review.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|